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The use of 5-methylcytosine demethylating agents in conjunction with inhibitors of histone deacetylation may offer a new therapeutic
strategy for lung cancer. Monitoring the efficacy of gene demethylating treatment directly within the tumour may be difficult due to
tumour location. This study determined the positive and negative predictive values of sputum and serum for detecting gene
methylation in primary lung cancer. A panel of eight genes was evaluated by comparing methylation detected in the primary tumour
biopsy to serum and sputum obtained from 72 patients with Stage III lung cancer. The prevalence for methylation of the eight genes
in sputum (21–43%) approximated to that seen in tumours, but was 0.7–4.3-fold greater than detected in serum. Sputum was
superior to serum in classifying the methylation status of genes in the tumour biopsy. The positive predictive value of the top
four genes (p16, DAPK, PAX5 b, and GATA5) was 44–72% with a negative predictive value for these genes X70%. The highest
specificity was seen for the p16 gene, and this was associated with a odds ratio of six for methylation in the tumour when this gene
was methylated in sputum. In contrast, for serum, the individual sensitivity for all genes was 6–27%. Evaluating the combined effect of
methylation of at least one of the four most significant genes in sputum increased the positive predictive value to 86%. These studies
demonstrate that sputum can be used effectively as a surrogate for tumour tissue to predict the methylation status of advanced lung
cancer where biopsy is not feasible.
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Lung cancer remains the leading cause of cancer-related death
among men and women in the United States largely due to the
lack of early diagnosis and the resistance of advanced disease to
standard radiation and chemotherapy (Jemal et al, 2002; Schiller
et al, 2002). These issues have prompted a renewed focus on
developing targeted therapy based on pathways that are altered
during the pathogenesis of lung cancer. Two targets that are being
exploited are the epidermal growth receptor family and vascular
endothelial growth factor (Auberger et al, 2006; Azim and Ganti,
2006; Dy and Adjei, 2006; Sandler and Herbst, 2006; Spicer et al,
2007). Although some patients have shown dramatic and sustained
responses to these therapies, overall response for non-small-cell
lung cancer (NSCLC) patients in Phase III trials has been modest,
albeit significant increases in survival have been reported
(Auberger et al, 2006; Azim and Ganti, 2006; Dy and Adjei, 2006;
Sandler and Herbst, 2006; Spicer et al, 2007). Patient selection
based on markers such as epidermal growth factor receptor
mutation or aneuploidy is likely important for maximising the
efficacy of these targeted therapies (Bunn et al, 2006). Unfortu-
nately, even preselecting patients based on dysfunction within the
targeted pathway is unlikely to yield sustained response in most
cases due to molecular heterogeneity of lung tumours.
One theoretical approach to this problem is to reverse the life–
threatening cancer phenotype to that of a less lethal cancer
phenotype. This strategy is quite difficult in the setting of genes
whose function has been altered through mutation or deletion, but
may prove feasible for epigenetic alterations that arise during lung
carcinogenesis. The silencing of genes through promoter hyper-
methylation is now recognised as a major and causal epigenetic
event that occurs during lung cancer initiation and progression
(Belinsky, 2005). Genes silenced by methylation are involved in
all aspects of normal cell function that include control of cell
proliferation, differentiation, and death. Gene silencing involves
methylation of cytosines in the gene promoter region, removal of
histone lysine tails, and other modifications of histones that
culminate in the establishment of chromatin modifications that
block transcription (Jones and Baylin, 2002; Herman and Baylin,
2003). Cytosine methylation appears to be dominant in transcrip-
tional repression, and inhibitors of the cytosine DNA-methyl-
transferases, 5-azacytidine, and 5-deoxyazacytidine (DAC), can
induce re-expression of genes silenced through promoter hyper-
methylation (Jones and Baylin, 2002; Herman and Baylin, 2003).
Importantly, while inhibitors of histone deacetylation (HDAC)
are not very effective in inducing re-expression of genes silenced
by promoter hypermethylation, such inhibitors can synergise
with demethylating agents to relieve transcriptional repression
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s(Cameron et al, 1999). These advances have now been translated
from the bench to the bedside to address whether restoring
expression of genes silenced by methylation can be used
therapeutically to treat cancer. Clinical trials with demethylating
agents alone or in combination with HDAC inhibitors have shown
promising responses in the treatment of myeloid malignancies
(Gore et al, 2006; Yang et al, 2006). Specifically, treatment with
5-azacytidine followed by the HDAC inhibitor, sodium phenyl-
butyrate, was associated with induction of acetylation of histones
H3 and H4. All responders showed cytogenetic effects and
demethylation of the p15 or CDH-1 promoters, while nonrespon-
ders failed to show any demethylation (Gore et al, 2006).
The extension of this targeted approach to solid tumours such
as those in the lung may also hold promise as a therapy. This
supposition is supported by our recent work in which combined
treatment with DAC and sodium phenylbutyrate reduced the
number of developing lung tumours in a murine model by 450%
(Belinsky et al, 2003). Similar to the strategy used in clinical trials
on myeloid malignancies, it will be important to determine
whether the drug combination causes demethylation of genes in
the lung tumours. Direct measurement of gene-specific promoter
methylation will not be feasible in many cases due to tumour
location and to patient compliance for the conduct of multiple
biopsies during the treatment period. An alternative strategy could
be to monitor methylation in a noninvasively accessible biological
fluid such as sputum or serum. The purpose of this study was to
determine the positive and negative predictive values of sputum
and serum for gene methylation in primary NSCLC. A panel of
eight genes was evaluated by comparing methylation detected in
the primary tumour biopsy to sputum and serum obtained from 72
patients with Stage III NSCLC.
MATERIALS AND METHODS
Subject enrollment
Subjects enrolled (n¼72) into this study were participating in the
randomised Phase III trial ‘Carboplatin, Paclitaxel, and Radio-
therapy, with or without Thalidomide’ through the Eastern Coast
Oncology Group (ECOG 3598). The criterion for participation in
the clinical trial was newly diagnosed, histologically confirmed
NSCLC that was either unresectable Stage IIIA or Stage IIIB
without pleural effusion. Patients were X18 years of age and had
no other active malignancies. In addition, no prior chemotherapy
within 5 years of enrollment onto this trial was allowed or
radiation to the tumour. Following enrollment in the clinical trial,
the patients were asked to participate in the correlative laboratory
studies by providing sputum, blood, and allowing receipt of
previously collected tumour tissue. All participants in the
laboratory study signed an informed consent at the enrolling
institution. The Lovelace Respiratory Research Institute (LRRI)
Review Board approved the conduct of this correlative study.
Selected demographics are summarised in Table 1. Cigarette
smoke exposure, pack years, and smoking duration are generally
not collected as part of clinical trials and thus were unavailable.
Sputum and blood collection and processing
On enrollment, a kit for collecting blood and sputum was sent to
the participating institution. Participants were provided with a
sterile specimen cup containing Saccomanno’s fixative in a self-
addressed return mailer (Kennedy et al, 1996). To increase the
probability that material from deep in the lung was obtained,
subjects received detailed verbal instructions by study personnel at
the participating institution and written instructions on how to
perform the technique. Briefly, for three consecutive mornings,
patients coughed deeply, and the resulting mucous was expecto-
rated into a cup. Two slides were prepared from the sputum
sample and underwent Papanicolaou staining for morphologic
examination by certified cytopathologists (Saccomanno, 1978). All
sputum samples, irrespective of adequacy (see Results), were
processed for methylation analysis by extensive mixing by vortex,
washed once with Saccomanno solution, and stored at room
temperature until analysed.
Blood (32cc) was collected by phlebotomy from all participants
into SST Vacutainer cell preparation tubes (Becton Dickinson and
Company, Franklin Lakes, NJ, USA). These tubes are designed to
separate serum from whole blood. Following separation, the serum
fraction was centrifuged at 1500r.p.m. to remove any contamina-
ting mononuclear cells. The serum fraction was then frozen at
 801C until processing for DNA isolation.
Nucleic acid isolation and methylation-specific PCR
DNA was isolated from sputum and tumour biopsies (1–15mm,
two to three sections) by protease digestion followed by phenol
chloroform extraction and ethanol precipitation. Plasma DNA
(10ml) was isolated using the QIAGEN blood maxi kit (Invitrogen,
Carlsbad, CA, USA). DNA was quantitated by spectrophotometer
at an absorbance of 260nm. In addition, a subset of DNA
recovered from serum samples was quantitated by the DNA dip-
stick test (Invitrogen). Quantitation by these two techniques
differed by o5%.
Promoter methylation was assessed in the p16, O
6-methyl-
guanine-DNA methyltransferase (MGMT), death-associated protein
kinase (DAPK), ras effector homolog 1 (RASSF1A), H-cadherin,
GATA5, PAX5 a, and PAX5 b genes. When these studies were
originally initiated, methylation assays were only conducted for
p16, MGMT, DAPK, and RASSF1A. The other genes were added
when results from our group demonstrated their potential for
predicting lung cancer risk and for early detection (Belinsky et al,
2005, 2006). These genes were also selected based on their
prevalence in lung cancer (X30%) and diversity of function
(Belinsky, 2004). Because of limited DNA available from some
tumour biopsies and serum, we were unable to assay for
Table 1 Summary of selected demographic variables
Variable
Stage III lung cancer
patient (n¼72)
Age














Mild atypia 26 (36)
Moderate atypia 6 (8)





a 39 (12, 148)
aMedian (range).
bInvasive cancers included SCC (n¼4), adenocarcinoma (n¼3),
and NSCLC (n¼4). SCC¼squamous cell carcinoma; NSCLC¼non-small-cell lung
cancer.
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smethylation of the H-cadherin, GATA5, PAX5 a, and PAX5 b genes
in all specimens.
Nested methylation-specific PCR (MSP) was used to detect
methylated alleles in DNA recovered from tumour tissue, sputum,
or serum. We used our nested MSP assay, described in detail
previously (Palmisano et al, 2000), because of its increased
sensitivity for the detection of promoter hypermethylation in
biological fluids and because of the ability to perform Stage 1
multiplex PCR. The amplification of four genes in a Stage 1 PCR
was needed due to the low amount of DNA recovered from the
serum and tissue biopsies from some subjects. To accurately
compare the prevalence for methylation in serum and sputum with
a sensitivity of 1 in 10–20000, 50–120ng of DNA were used for
Stage 1 PCR following modification with bisulphite. Because of
tissue degradation from formalin fixation and storage in paraffin,
sensitivity was approximately 1 in 500 even with the nested MSP
approach. PCR primers for Stages 1 and 2 have been described
elsewhere (Palmisano et al, 2000; Belinsky et al, 2002; Palmisano
et al, 2003). A subset of samples (20%) that gave positive
methylation products also was analysed by methylation-sensitive
restriction enzyme digestion of the resulting PCR product. The
restriction digestion allows one to examine the methylation state of
CpGs within the amplified PCR product and serves as a control for
false priming. Digestion within at least one of the restriction sites
was seen for all samples, positively confirming methylation.
Statistical methods
Categorical variables were summarised with percentages and
continuous variables were summarised with medians and ranges.
Each gene was examined separately, but to assess the importance
of multiplicity, a methylation index was based on obtaining the
number of genes that were methylated among the panel of eight
genes. Because some of the samples were missing methylation data
for four of the genes, a second methylation index based on the
panel of four genes with complete data (p16, MGMT, RASSF1A,
and DAPK) was also created. Fisher’s exact test was used to
compare the frequency of methylation between groups based on
gender and characteristics of the sample or tumour, such as
adequacy or tumour type. The two-sample t-test was used to
compare DNA concentration in serum between methylated and
unmethylated samples for each gene. Paired sputum and serum
samples were compared for differences in methylation frequency
with the exact form of McNemar’s test. In comparisons of
methylation results for sputum and serum samples with tumour
samples, sensitivity, specificity, positive and negative predictive
value were calculated, along with 95% confidence intervals. To
further explore the association between the sputum and serum
samples and the tumour sample, logistic regression was used to
obtain odds ratios for tumour methylation based on methylation
status of the sputum or serum. All analyses were conducted in SAS
version 9.1.3.
RESULTS
Tumour histology, sputum cytology, and DNA recovery
from serum
Adenocarcinoma comprised the major histology (40%) followed by
31% of the tumours being classified as squamous cell carcinoma
(SCC, Table 1). Nineteen percent of tumours were classified as
NSCLC due to insufficient amount of tissue to classify by specific
histology.
Sputum adequacy defined as the presence of deep lung
macrophages or Curschmann’s spiral (Saccomanno, 1978) was
observed for 87% of the specimens collected. Atypia ranging from
mild to severe was seen in 35 of the sputum specimens (Table 1).
Lung cancer diagnosed as SCC, adenocarcinoma, or NSCLC was
detected in sputum from 11 of 72 cases. The median amount of
DNA recovered from serum was 39ngml
 1 (Table 1).
Prevalence for gene methylation in tumour, sputum, and
serum
The prevalence for methylation of the eight genes evaluated in
tumours ranged from 15% for MGMT to 47% for the p16 gene
(Table 2). With the exception of MGMT, these findings approx-
imate to that seen in previous studies for methylation of these
genes in NSCLC (Belinsky, 2004). P16 and GATA5 were the two
most common genes methylated in sputum (B40%, Table 2). The
remaining genes were methylated at prevalences from 21 to 32%.
The prevalence for methylation of these genes in sputum was
0.7–4.3-fold greater than detected in serum. Significant differences
(Po0.05) between sputum and serum were seen for methylation
for all genes except PAX5 a and GATA5. There were no significant
differences in prevalence for methylation in tumour or serum by
gender (not shown). Interestingly, relatively more sputum samples
from men were methylated for the p16, PAX5 b, and GATA5 genes
than for women (Po 0.05).
The influence of histology, SCC, or non-SCC on methylation in
tumours and detection in sputum and serum was also assessed.
Non-SCC comprised all other histological types described in
Table 1. The differences seen did not reach statistical significance
due to the decrease in sample size when comparing effect of
histology, but were a greater prevalence for methylation of the
p16 (62 vs 39%, P¼0.09), and DAPK genes (46 vs 22%, Po 0.05)
in SCC compared to non-SCC. P16 was also more commonly
methylated in sputum from SCC than non-SCC cases (54 vs 33%,
P¼0.09), while the opposite scenario was observed for this gene in
serum (8 vs 28%, P¼0.07). The effect of adequacy and positive
sputum cytology on the detection of gene methylation was also
assessed. As seen in previous studies (Belinsky et al, 2005, 2006),
no association was observed between adequacy and our ability to
detect gene methylation. This likely reflects the fact that the
classification of adequacy is based largely on the presence of deep
Table 2 Prevalence of gene methylation and multiplicity in tumour,
sputum, and serum
Tumour Sputum Serum
Gene (Number positive (%))
a
p16 34/72 (47) 29/72 (40) 15/72 (21)*
MGMT 11/72 (15) 23/72 (32) 4/72 (6)*
RASSF1A 31/72 (43) 19/72 (26) 7/72 (10)*
DAPK 22/72 (31) 22/72 (31) 7/72 (10)*
HCAD 17/56 (31) 19/72 (26) 3/53 (6)*
PAX5 b 22/56 (39) 15/72 (21) 3/53 (6)*
PAX5 a 20/56 (36) 22/72 (31) 8/45 (18)
GATA5 19/56 (34) 31/72 (43) 10/45 (22)
Four gene panel
b
0 15/72 (21) 21/72 (29) 43/72 (60)*
1 27/72 (38) 21/72 (29) 25/72 (35)
2 19/72 (26) 20/72 (28) 4/72 (6)*
X3 11/72 (15) 10/72 (14) 0/72 (0)
Eight gene panel
c
0 6/56 (11) 10/72 (14) 20/45 (44)*
1 12/56 (21) 18/72 (25) 12/45 (27)
2 9/56 (16) 12/72 (17) 10/45 (22)
X3 29/56 (52) 32/72 (44) 3/45 (7)*
aSample size varied for tumour and serum due to limiting amount of DNA when
additional four genes were added for methylation screening.
bp16, MGMT, RASSF1A,
DAPK.
cp16, MGMT, RASSF1A, DAPK, PAX5 a, PAX5 b, H-Cadherin, GATA5.* Po 0.05
when comparing prevalence of methylation in serum to sputum.
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slung alveolar macrophages in the sputum sample, but not the
presence of epithelial cells that are shed from both the airways and
alveolar regions. These cells are the source of the malignant or
precancerous cells that harbour the methylated genes. Sputum
specimens were divided into those that were positive for cancer or
moderate/severe atypia (n¼20) and compared to specimens where
no abnormality or inadequacy was observed (n¼25). The
prevalence for individual gene methylation was always greater in
the atypia/cancer group compared to the no abnormality/
inadequate group (Table 3). In contrast, no association was seen
between the detection of gene promoter methylation and the
amount of freely circulating DNA in serum (P40.1 for each gene).
Increased multiplicity for gene methylation in sputum
compared to serum
The presence of at least one, but preferably multiple biomarkers
(methylated genes) in the primary tumour should increase the
efficiency of monitoring the effectiveness of demethylating therapy
by evaluating the biological fluid. Using the four-gene panel, at
least one gene was methylated in 79% of tumours, while 15% of
tumours were methylated for three or more genes (Table 2). The
detection of any methylated gene in tumours improved to 89%
by increasing the panel of genes examined to eight and improved
detection also associated with greater than half of the tumours
being positive for methylation of three or more genes. With respect
to sputum, increasing the gene panel to eight reduced the number
of samples that were negative for gene methylation and
substantially increased the multiplicity for methylation (Table 2).
Only 10 of 72 cases were negative for methylation of all genes
in sputum, while three or more genes were methylated in 44% of
sputum samples. In contrast, the presence of gene methylation in
serum was significantly lower than in sputum. Even with the eight-
gene panel, no methylated genes were detected in 44% of cases,
while only 7% of cases were positive for three or more methylated
genes in DNA recovered from serum (Table 2).
Correlation of gene promoter methylation in sputum and
serum with tumour methylation
Sputum was superior to serum in classifying the methylation status
of genes in the tumour biopsy. Sensitivity and specificity for five
genes (p16, MGMT, DAPK, PAX5 b, GATA5) ranged from 45 to
63% and 62 to 79%, respectively (Table 4). The highest specificity
was seen for p16, and this specificity was associated with an odds
ratio of six for methylation in the tumour when this gene was
methylated in sputum. With the exception of MGMT where the
methylation prevalence was lower in the tumours than sputum,
the positive predictive value for the other four genes was 45–72%.
The negative predictive value for these five genes was X70%. In
general, the sensitivity and specificity of sputum for classifying
methylation of these eight genes did not differ between SCC and
non-SCC. The one exception was p16, whereas for SCC, sensitivity
and specificity was increased to 81 and 90% with a positive and
negative predictive value of 93 and 75%, respectively. In contrast,




Gene (Number positive (%))
p16 11/20 (55) 8/25 (32)
MGMT 7/20 (35) 7/25 (28)
RASSF1A 10/20 (50) 4/25 (16)*
DAPK 9/20 (45) 5/25 (20)
HCAD 8/20 (40) 1/25 (4)*
PAX5 b 6/20 (30) 5/25 (20)
PAX5 a 9/20 (45) 3/25 (12)*
GATA5 11/20 (55) 7/25 (28)
aIncludes the detection of moderate and severe atypia and all cancers in the sputum
specimen. *Po 0.01 when comparing prevalence of methylation in normal/
inadequate to atypical/cancer.
Table 4 Evaluation of sputum and serum for predicting methylation state in tumour biopsy
OR Sensitivity (%) Specificity (%) Positive predictive value (%) Negative predictive value (%)
Gene Fluid N (95% confidence interval)
p16 Sputum 72 6.1 (2.1, 17.2) 62 (45, 78) 79 (66, 92) 72 (56, 89) 70 (56, 83)
Serum 72 0.7 (0.2, 2.2) 18 (5, 30) 76 (63, 90) 40 (15, 65) 51 (38, 64)
MGMT Sputum 72 2.0 (0.5, 7.4) 45 (16, 75) 70 (59, 82) 22 (5, 39) 88 (79, 97)
Serum 72 22.5 (2.1, 243.2) 27 (1, 54) 98 (95, 100) 75 (33, 100) 88 (81, 96)
RASSF1A Sputum 72 1.3 (0.4, 3.6) 29 (13, 45) 76 (62, 89) 47 (25, 70) 58 (45, 72)
Serum 72 3.7 (0.7, 20.8) 16 (3, 29) 95 (89, 100) 71 (38, 100) 60 (48, 72)
DAPK Sputum 72 2.6 (0.9, 7.6) 45 (25, 66) 76 (64, 88) 45 (25, 66) 76 (64, 88)
Serum 72 0.9 (0.2, 5.0) 9 (0, 21) 90 (82, 98) 29 (0, 62) 69 (58, 80)
HCAD Sputum 56 1.2 (0.3, 4.3) 29 (8, 51) 74 (61, 88) 33 (9, 57) 71 (57, 85)
Serum 48 2.5 (0.1, 43.7) 7 (0, 21) 97 (91, 100) 50 (0, 100) 72 (59, 85)
PAX5 a Sputum 56 1.0 (0.3, 3.4) 23 (5, 40) 76 (62, 91) 38 (12, 65) 60 (46, 75)
Serum 48 1.0 (0.1, 11.9) 6 (0, 18) 94 (85, 100) 33 (0, 87) 67 (53, 80)
PAX5 b Sputum 56 2.5 (0.8, 7.8) 45 (23, 67) 75 (61, 89) 50 (27, 73) 71 (57, 85)
Serum 45 0.6 (0.1, 3.5) 13 (0, 31) 80 (66, 94) 25 (0, 55) 65 (49, 80)
GATA5 Sputum 56 2.8 (0.9, 8.8) 63 (41, 85) 62 (47, 78) 46 (27, 65) 77 (62, 92)
Serum 45 0.4 (0.1, 2.3) 13 (0, 31) 73 (58, 89) 20 (0, 45) 63 (47, 79)
OR¼odds ratio.
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sfor serum, the individual sensitivity for all eight genes was only
6–27%, although specificity was 73–98% (Table 4). The positive
predictive value for methylation in serum exceeded 70% for two
genes, MGMT and RASSF1A. Combining methylation results from
sputum and serum did not significantly improve sensitivity or
specificity for predicting the methylation status in the tumour
biopsy.
A key question is the overall predictive power of a gene panel
assayed in sputum to accurately classify the methylation status
of at least one of those genes in the tumour. This was evaluated
by looking at the combined effect of having methylation of p16,
DAPK, PAX5 b,o rGATA5 in the sputum. These genes were
selected because their individual positive and negative predictive
values were superior to the other genes. The composite positive
predictive value for these four genes was 86%; however, the
negative predictive value was 42%. The lower negative predictive
value is due largely to the fact that although 43 of the 56 tumours
were methylated for at least one of these genes, the matched
sputum from 11 of these methylated tumours was negative for
methylation of any of the four genes.
DISCUSSION
These studies demonstrate the superiority of sputum over serum
as a surrogate for tumour tissue to predict the methylation status
of advanced lung cancer where biopsy is not feasible. Gene
methylation of both SCC and non-SCC tumours could be predicted
through analysis of sputum substantiating the use of this fluid
for monitoring both central and peripheral lung tumours. The
false-positive methylation seen in sputum likely stems from the
extensive field cancerisation induced by smoking and from which
the lung cancer arises (Slaughter et al, 1953). In contrast, false
negatives likely occur because of the lack of exfoliation of tumour
or atypical cells into the sputum at amounts needed for detection.
This conclusion is supported by the differences in prevalence seen
for all eight genes evaluated for methylation between sputum
samples positive for atypia or cancer vs samples that were
cytologically normal or inadequate.
Serum proved to be a poor surrogate to predict the methylation
status of the tumour, largely because of the low prevalence for
detection of methylated genes in this fluid. Our gene prevalences
for p16, MGMT, DAPK, and RASSF1A methylation in serum are
very similar to that observed by Fujiwara et al (2005) in their study
of serum from all stages of NSCLC and in our previous study of
lung cancer survivors that examined free DNA recovered from
plasma (Belinsky et al, 2005). Both Fujiwara et al (2005) and
Esteller et al (1999) saw no association between methylation
detection in serum and tumour stage. This low sensitivity is likely
because the tumours are not releasing free DNA through
apoptosis, or because the released DNA is too fragmented to
allow detection of the methylated alleles of the interrogated genes.
This conclusion is consistent with the fact that the median amount
of DNA recovered from serum in this study did not differ from that
recovered from lung cancer survivors, smokers, or never smokers
(Belinsky et al, 2005). There has been a report of increased
circulating DNA in blood from lung cancer patients; however, this
finding was likely influenced by the blood separation protocol that
did not conduct a second centrifugation step to remove
contaminating mononuclear cells (Sozzi et al, 2001).
A key question from our study is what is the biological
significance of detecting methylation of genes in the serum? The
presence of methylation in serum could reflect the invasive
potential of the tumour, a conclusion that will be evaluated
through the clinical trial being conducted on these patients that
will examine the relationship between the presence of methylation
in serum and the response to therapy. For five of the eight
genes, the positive predictive value in serum was p40%. This
probably reflects both the release of DNA from preinvasive
lesions in the lungs and the contribution of other age-related
diseases to the DNA pool recovered in blood. For example, in our
previous study, two participating never smokers reported a past
diagnosis of ovarian cancer and methylation of the p16 gene was
detected in DNA recovered from their plasma (Belinsky et al,
2005).
Field defects involving preneoplastic changes have been
described in which histologically negative bronchial margins of
resected NSCLC exhibit frequent hypermethylation changes in
multiple genes that often reflect the methylation status of the
tumour (Guo et al, 2004). In addition, our previous studies have
detected gene methylation in bronchial epithelial cells obtained
from cancer-free lung lobes of patients with cancer (Belinsky et al,
2002). This field cancerisation likely accounts for our ability to
detect methylation in sputum from the majority of cases in spite
of only being able to observe moderate to severe atypia (both
predictive of cancer risk) or frank carcinoma in sputum from 20 of
72 cases. The presence of field cancerisation may be advantageous
for monitoring the effectiveness of demethylating therapy because
both tumour and lung tissue will be exposed to the therapy. In this
study, p16 proved to be the superior marker with respect to both
positive and negative predictive value. This is likely due to the high
prevalence (B50% of tumours methylated) and the early stage of
tumour development in which this gene is silenced by methylation
(Belinsky et al, 1998; Belinsky, 2004). However, in order to assess
response to therapy, a gene panel is needed whose composite
methylation in sputum identifies the majority of tumours. A panel
of four genes that included p16, DAPK, PAX5 b, and GATA5 was
methylated in 77% of tumours and had a combined positive
predictive value of 86%. It will likely be necessary to evaluate
response based not on one gene, but on a methylation index
(number of genes). This is because unlike myeloid malignances
where the cell population evaluated (bone marrow) is homo-
geneous, sputum is very heterogeneous negating the ability to
detect quantitative differences in the extent of individual gene
methylation by sequencing or quantitative real-time MSP. The
methylation index is proving to be a good measure for predicting
lung cancer risk. Our recent nested case–control study revealed
that the concomitant methylation of three or more of a panel of six
genes was associated with a six-fold increased risk for lung cancer
(Belinsky et al, 2006). A sensitivity and specificity of 64% was seen
for identifying incident lung cancer cases 3–18 months prior to
clinical diagnosis. We are entering a new era of targeted cancer
therapy in which future clinical trials will evaluate the efficacy of
demethylation therapy on tumour growth and field cancerisation
and the ability of the gene methylation index in sputum to predict
response.
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